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Summary. Pyrimidinones, like 2-amino-5-bromo-6- 
phenyl-4-pyrimidinone (bropirimine), are potent immuno- 
modulators. Natural killer cell activity and macrophage 
cytotoxicity are increased after bropirimine treatment, an 
effect exerted through induction of cytokines. Up to now, 
the interferons have been supposed to be the main media- 
tors but we have found that tumour necrosis factor c~ 
(TNFc0 can also be an important mediator of the bropir- 
imine antitumour effects. Increased serum levels of TNFc~ 
were seen in rats after intraperitoneal dministration of 
200 mg/kg bropirimine on 2 consecutive days. We also 
found that the tumour-growth-inhibiting effect of the drug 
on a colon carcinoma in rats could be reduced about 40% 
by giving the rats rabbit anti-TNFcz serum just prior to drug 
treatment. These results indicate that bropirimine can in- 
duce the release of TNFc~ in vivo and that this endogenous 
TNFc~ may be important as far as the antitumour effect of 
the drug is concerned. 
Introduction 
Immunotherapy is a promising modality in the treatment of 
cancer. Treatment with cytokines, sometimes in combina- 
tion with adoptive transfer of immunocompetent cells, is 
successful in several animal models as well as in patients 
with different ypes of malignancies, especially renal cell 
carcinoma or melanoma [4, 18, 21, 28, 32]. The cytokines 
interleukin-2, the interferons, and tumour necrosis factor o~ 
(TNFcz) have been most frequently studied. We have been 
working for some years with interferon 7 and TNF~ in 
various experimental tumour models [8, 14, 15, 25]. 
TNF~ appeared to have a growth-inhibiting effect in 
some models [14, 15], but in those models resembling the 
clinical situation best, i.e. liver metastases of colon carci- 
noma, a significant growth inhibition could not be demon- 
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strated espite the use of different administration schedules 
[25]. Therefore we, and others, concluded that TNFc~ 
should be used in combination therapy, for example with 
other biological response modifiers, and it has indeed been 
demonstrated that combining TNFc~ with intefferon y or c~ 
results in synergistic antitumour effects [l, 3, 27, 39]. 
Another suggested possibility of increasing the effi- 
cacy of exogenous TNFc~, is to administer it at the time that 
endogenous TNF~ is release& This therapy has been re- 
ferred to as endogenous-exogenous therapy [9]. Examples 
of TNFcz-inducing agents are endotoxin (lipopolysac- 
charide) and OK432. The former is a strong TNFcz inducer 
but can hardly be used clinically because of severe toxicity, 
while the latter is a strong and far less toxic TNFc~ inducer 
[10, 26]. 
In search for other TNFc~-inducing agents, the known 
interferon inducer bropirimine was tested in vivo. We ex- 
amined whether it can cause TNFc~ release by measuring 
serum levels of TNF(z after intraperitoneal (i.p.) adminis- 
tration of bropirimine in rats. Furthermore, we examined 
the effect of bropirimine treatment on a colon carcinoma 
and a rhabdomyosarcoma as compared to TNFc~ treatment. 
Finally, we examined whether the antitumour effect of 
bropirimine could be blocked by pretreatment with rabbit 
anti-TNFo~ serum. 
Materials and methods 
Animals. Male rats of the inbred WAG (RT1 u) strain were obtained from 
Harlan-CPB (Austerlitz, The Netherlands). The animals were bred under 
specific-pathogen-free conditions and were 10-14 weeks old when used. 
Tumours. A 1,2-dimethylhydrazine-induced, moderately differentiated 
colon adenocarcinoma (CC531) and a rbabdomysarcoma (R2K), trans- 
plantable insyngeneic WAG rats, were used [13, 19]. CC531 was main- 
tained in vitro in RPMI-1640 medium supplemented with 5% fetal calf 
serum and R2K in Dulbecco's modified Eagle medium with 10% new- 
born calf serum (sera were screened for virus and Mycoplasma infec- 
tions). The media were supplemented with l% penicillin (5000 IU/ml), 
1% streptomycin (5000 gg/tal) and 1% L-glutamine (200 mM), all ob- 
tained from Gibco (Paisley, UK). Before use, the cells were trypsinized 
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Fig. 1. Effect of different concentrations of recombinant murine tumour 
necrosis factor c~ (rMuTNF~)(U/ml) on in vitro growth of tumour cell 
lines CC531 and R2K after incubation for 48 h. Viability was measured 
using the MTT assay; absorbance (A) was measured at 515 nm 
(5 min, 37 ° C), centrifuged (5 min, 700 g), resuspended in their media 
and counted. Viability was measured using Trypan blue (0.3% in a 0.9% 
NAC1 solution); it consistently exceeded 95%. 
In vitro testing of tumour celI lines for response to TNF. Tumour cells 
were seeded at I x 104 cells/well in flat-bottomed 96-well microtiter 
plates (Costar, Cambridge, Mass.) in a final volume of 0.2 ml me- 
dium/weil, and incubated at 37 ° C in 5% CO2 for 48 h in the presence of 
different concentrations of recombinant murine tumour necrosis factor c~ 
(rMuTNFc0. Concentrations of rMuTNFcc were 0 U/tal, 50 U/ml, 
100 U/tal and 5000 U/ml. Growth of turuour cells was measured using an 
MTT (3-4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl t trazolinrubromide 
assay (for details ee [25]). Absorbance was read at 515 nm using a Flow 
Titertek Multiskan (McLean, Va.) plate reader. Eight replicate wells 
were used for each concentration tested. 
Agents. rMuTNFct was kindly provided by Dr. W. Fiers (Lab. Molecular 
Biology, Geht, Belgium). The preparation was over 99% pure, contain- 
ing less than 4 ng endotoxin/mg protein. 2-Amino-5-bromo-6-phenyl-4- 
pyrimidinone (bropirimine) was produced as reported previously [31] 
and provided by the Upjohn Company, Kalamazoo, Mich., USA. 
Rabbit anti-(mouse-recombinant TNFct) serum (RaTNFS) was pre- 
pared in our laboratory. Rabbits were three-times irnmunized with 
rMuTNFc~ in combination with Freund's adjuvants (25 gg 
rMuTNFcdimmunization, administered intracutaneously). Blood was 
collected 1week after the last immunization, serum was stored and tested 
for anti-TNFct activity. RaTNFS had a neutralizing capacity of 
100000 U/tal serum in the L929 bioassay (see next paragraph). In vivo 
0.5 ml RaTNFS given intravenously (i.v.) protected rats against he 
lethal effect of 20 gg rMuTNFc~ given subsequently. Rats not pretreated 
with RaTNFS (n = 2) both died while pretreated rats (n = 2) survived 
after MuTNFct administration without signs of toxicity. 
Table 1, Sensitivity of CC531 and R2K for rMuTNFa or bropirimine ~ 
Treatment Mean tumour n Tumour weight (mg) 
weight (mg) 
+_SD 
Tumour CC531 
Control 13+_ 3 12 8,9,10,11,12,13,14,16,16,16,17,19 
rMuTNFc~ a 7+_ 3 12 2,4,6,7,7,7,7,8,9,9,11,12 
Control 27+_ 11 10 10,18,22,22,24,24,26,32,35,52 
Bropirimine* 10_+ 5 8 3,5,8,12,12,12,14,17 
Tumour R2K 
Control 26 + 10 10 11,13,21,22,24,26,30,35,40,41 
rMuTNFa 24+_ 9 10 11,14,17,18,26,28,29,32,33,37 
Control 20+_ 5 12 11,14,15,17,17,19,21,22,24,25,26,28 
Bropirimine* 12+_ 6 10 5,6,6,11,11,12,14,15,16,24 
a In vivo sensitivity of tumours CC531 and R2K for rMuTNFc~ and 
bropirhnine. A sub-renal-capsule assay was performed in rats. Control 
rats received i.v. 1 ml HBSS on days 0, 2 and 4 and 1 ml phosphate- 
buffered saline i.p. on days 0 and 1 after tumour implantation. 
rMuTNFc~-treated rats received i. v. 4 ~tg rMuTNFct on days 0, 2 and 4; 
bropirimine-treated rats received i.p. 200 mg/kg bropirimine on days 0 
and 1 after tumour implantation. Animals were sacfificed at day 7 and 
tumours were enucleated and weighed. Both rMuTNFct and bropirimine 
had a significant growth-inhibiting effect on tumour CC531 (P <0.01 and 
P <0.05 respectively). Growth of tumour R2K was significantly inhibited 
by bropifimine (P <0.01) but rMuTNFc~ did not inhibit growth of R2K 
* Significantly different from conlrol 
received Hanks balanced salt solution (HBSS) i.v. and phosphate- 
buffered saline i.p. (control treatment). Each treaunent was tested twice 
on both tumours. 
In order to study the TNFt~-inducing capacity of bropirimine, rats 
received 200 mg/kg of the drug i. p. on 2 consecutive days (the therapeu- 
tic regimen). During the second day blood samples were collected and 
serum was stored at -20 ° C. Blood samples were taken 5 min prior to the 
second bropirimine administration a d after 1, 2, 3, 4 and 6 la. Control 
animals received HBSS i.p. 
In another series of experiments, using the sub-renal-capsule assay 
model, we tested whether the antitumour effect of bropirimine against an 
in vivo proven TNF-sensitive tumour (CC531) could be blocked by 
pretreatment with 0.25 ml RaTNFS i.v. On days 0 and 1 the rats received 
200 mg/kg bropirimine i.p. immediately after an i.v. injection of 
0.25 HBSS, normal rabbit serum or RaTNFS. 
Statistical nalysis. For measurement of significance of difference in the 
sub-renal-capsul assay, the Wilcoxon's rank sum test was performed. For 
measurement of significance between control and bropirimine-treated 
groups in the TNFct-inducing experiments, Student's t-test was used for 
the various time points. 
Results 
TNFo~ assay. For measurement of TNF« in the serum samples of the rats 
a standard cytotoxicity assay for TNFa, using the L929 cell line, was 
performed. Cells were seeded at5 x 105 cells/well (100 gl) in flat-bot- 
tomed 96-well microtiter plates in the presence of actinomycin-D (rinn 
concentration 1 gg/ml). Sera, 50 and 100 times diluted, were added (to a 
final volume of 200 gl) and after 20 h the cell survival was estimated by 
the colorimetric MTT assay. Absorbance was read at 515 nm. The TNFct 
concentrations were calculated by comparison with a standard curve. 
Experimentaldesign. To test he sensitivity of CC531 and R2K for TNFct 
and bropirimine in vivo, a sub-renal-capsule assay [ 13, 25] was perform- 
ed. In summary, apiece of tumour of about 10 mg is placed underneath 
the renn capsule of the rats, whereafter treatment is starte& After 1 week 
animals are sacrificed, tumours enucleated and subsequently weighed. 
Treatment consisted of i.v. injections of 4 gg/kg rMuTNFc~ 
(rMuTNFc~ treatment) on days 0, 2 and 4 or i. p. injections of 200 mg/kg 
of bropirimine (bropirimine/treatment) o  days 0 and 1. Control animals 
In vitro sensitivity ofCC531 and R2K for rMuTNF~ 
Both  cel l  l ines were  re lat ive ly  insens i t ive  to the cyto- 
stat ic /cyto lyt ic  act iv i ty  of  rMuTNFc~ as measured  after 
48 h incubat ion  (Fig. 1). rMuTNFc~ caused on ly  a minor ,  
though s igni f icant ,  reduct ion  in the number  of  v iab le  cel ls 
in both  cel l  l ines at a concent ra t ion  of  5000 U 
rMuTNFc~/ml .  
In vivo sensitivity ofCC531 and R2K for rMuTNFo~ 
or bropirimine 
RMuTNFc~ as we l l  as brop i r imine  d id have  a s ign i f icant  
g rowth- inh ib i t ing  ef fect  on  tumour  CC531,  wh i le  on ly  
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Fig. 2. Serum TNFo~ levels in rats after treatment with bropirimine 
(200 mg/kg i.p. on 2 consecutive days) or after treatment with Hanks 
balanced salts olution (HBSS; 1 ml i. p. on 2 consecutive days) _+ SEM. 
Samples were taken 5 min prior to the second administration a d 1, 2, 3, 
4 and 6 h thereafter. TNF« was measured nsing the L929 bioassay. At 1, 
2, 3, 4 and 6 h. TNFc~ serum levels were significantly increased 
(P <0.005 for each time point) in the bropirimine-treated group as com- 
pared to HBSS controls 
bropirimine could inhibit growth of tumour R2K. Agents 
were tested twice on each tumour (Table 1; results of one 
of the experiments i  shown). Efficacy for both agents was 
of the same order of magnitude for colon cancer CC531. 
In vivo TNF o~ induction by bropirimine 
Administration of 200 mg bropirimine/kg i.p. on 2 consec- 
utive days (the therapeutic regimen) resulted in a signifi- 
cant increase in TNFc~ serum levels. TNFo~ serum levels 
peaked 1 h after the second administration and remained 
significantly elevated for up to 6 h at least. Mean TNFc~ 
serum levels in controls were surprisingly high at 5 min 
because two of the control rats had unexplained high TNFo~ 
starting levels. 
Blocking of the antitumour effect of bropirimine against 
CC531 in vivo by RaTNFS 
In two experiments RaTNFS partially blocked the tumour- 
growth-inhibiting effect of bropirimine on CC531 (Table 
2). In the first experiment, the effect of bropirimine + 
RaTNFS was 59% of the effect of bropirimine + HBSS, 
while in the second experiment the effect of bropirimine + 
RaTNFS was 57% of the effect of bropirimine + normal 
rabbit serum. 
Discuss ion 
Although it has been described how bropirimine induces 
the release of lymphokines other than interferon [20], its 
TNFo~-inducing capacity has never been emphasized 
before. This capacity could be very interesting in the light 
of its role in tumour therapy. So far, the antitumour effects 
of bropirimine were believed to be especially mediated by 
Table 2. Blocking of the antitumour effect of bropirimine on colon 
cancer CC531 by pretrealment with rabbit anti-(mouse r combinant 
TNFc~) serum (RaTNFS) a
Pretreatment/ Mean tumour n Tumour growth (mg) 
treatment growth (mg) 
_+SD 
Experiment 1 
Control/control 25 _+ 1 
Control/bropirimine* 4 _+ 2 
RaTNFS/bropirimine** 13_+8 
Experiment 2 
Control/control 13 _+ 5 
NRS/bropirimine* 3 + 4 
RaTNFS/bropirimine* ** 7_+5 
12 2,13,18,25,25,25,26,26,27, 
31,31,51 
10 0,1,3,4,5,5,5,6,6,6 
12 0,0,1,9,13,13,14,18,19,21, 
22,22 
12 5,7,7,7,10,14,14,14,17,17, 
20,20 
6 -2,-1,1,5,5,7 
8 1,2,2,4,11,11,12,12 
a In two separate xperiments he effect of pretreatment with RaTNFS 
on the antitumour effect of bropirimine on tumor CC531 in a sub-renal- 
capsule assay was measured. Animals were pretreated with HBSS (con- 
trol), normal rabbit serum (NRS) or rabbit anti-TNFc~ serum (0.5 ml i. v. 
just prior to treatment), and then treated with HBSS (control, 1 ml i. p.) or 
bropirimine (200 mg/kg i.p.) at days 0 and 1 after tumour implantation. 
After 7 days animals were sacrificed, tumours were enucleated and 
weighed and tumour growth was calcutated. In both experiments, groups 
treated with bropirimine, regardless of pretreatment, were significantly 
different from the HBSS-treated groups (P <0.01). In both experiments 
the groups pretreated with HBSS or NRS and subsequendy treated with 
bropirimine were significantly different from the groups pretreated with 
RaTNFS and treated with bropirimine (P <0.01) 
* Significantly different from control/control 
** Significantly different from control/control and from control/bropir- 
imine 
*** Significantly different from control/control and from NRS/bropir- 
imine 
endogenous interferons, leading to increased natural killer 
(NK) cell and macrophage cytotoxicity [5, 12]. The results 
of this study suggest that endogenous TNFc~ can also be an 
important effector of bropirimine activity. In rats, 
200 mg/kg bropirimine, given i.p. on 2 consecutive days, 
resulted in increased serum levels of TNF~. All rats in the 
bropirimine-treated group had high starting levels of serum 
TNFoq indicating that single bropirimine administration 
does also induce TNF release (TNFo~ serum levels were 
only measured after the second bropirimine administra- 
tion). The high mean TNFo~ serum levels in the control 
group at 5 min were due to two of the control animals. 
These animals had persistently higher TNFo~ levels 
throughout the experiment than the other rats in the control 
group, in whose serum virtually no TNFc~ could be demon- 
strated. The tumour-growth-inhibiting effect of bropir- 
imine against an in vivo proven TNFc~ sensitive tumour, 
could be reduced about 40% by pretreatment with rabbit 
anti-TNFc~ serum. This study shows that TNFc~ is only one 
of the mediators through which bropirimine xerts its anti- 
tumour effect, since the in vivo TNFc~-insensitive tumour 
R2K responded as well to bropirimine as did tumour 
CC531. Bropirimine has already been shown to be a potent 
immunotherapeutic agent against different ypes of experi- 
mental cancer [5, 16, 17], which is confirmed by this study. 
Treatment with bropirimine often resulted not only in 
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growth inhibition but even in tumour egression. Earlier 
observations in our laboratory have shown that bropirimine 
does not only inhibit growth of tumour CC531 in a sub- 
renal-capsule assay but also in an artificial liver metastases 
model [6]. 
The TNF(x-inducing capacity of bropirimine is the 
more interesting with regard to the so-called endogenous- 
exogenous therapy. This therapy seems to have better anti- 
tumour efficacy than either induction of endogenous TNFc~ 
or administration f exogenous TNFc~ [9]. So far, endo- 
genous-exogenous therapy has been performed using the 
streptococcal preparation OK432 as the TNFc(-inducing 
agent [26]. Like bropirimine, OK432 causes the release of 
TNFo~ [23] and it increases macrophage [23], NK cell, [33] 
and large granular lymphocyte cytotoxicity [29]. It also 
induces the release of interferon [22]. Peak levels of TNF(x 
in serum of mice after OK432 treatment [24] were in the 
same order as peak levels of TNF~z in serum of rats after 
bropirimine treatment in this study. Although comparison 
of results obtained in rats or mice can never lead to final 
conclusions, bropirimine might well be an alternative to 
OK432 in endogenous-exogenous therapy. It has already 
been reported that bropirimine and TNFo~ have synergistic 
antitumour effects [13]. 
This study emphasizes again that in vitro findings, as 
far as biological response modifiers are concerued, o not 
predict the in vivo outcome. Both tumours CC531 and 
R2K were in vitro relatively insensitive to the cyto- 
static/cytolytic activity of rMuTNFc~, but growth of 
tumour CC531 was strongly inhibited in vivo by treatment 
with rMuTNFo~. 
The recognition of bropirimine as being a TNFc~ in- 
ducer in vivo may well explain a previously reported effect 
of the drug that could not be explained on the basis of its 
interferon-inducing capacity. It appeared that bropirimine 
could protect mice against listeriosis [2]. This protecting 
effect of the drug against an infection with Listeria mono- 
cytogenes, remained when the mice were pretreated with a 
potent anti-interferon a tibody, indicating that this effect 
was not due to endogenous interferon. It is known that 
endogenous TNFc~ protects mice against infection with 
Listeria, especially in the early stages of the infection 
[7, 11], so the protecting effect of bropirimine could well 
be mediated by endogenous TNFc~. 
From the results presented in this study it can be con- 
cluded that bropirimine can induce the release of TNFc~ in 
rats; this endogenous TNFc~ can be important as rar as the 
antitumour effects of bropirimine are concerned and could 
make the drug an even more important, immunomodula- 
tory, antitumor agent. 
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